Table 3.
Studies evaluating biomarkers predictive of treatment response in PsA.
| Reference | Outcome measure | Treatment | Biomarker | Outcome |
|---|---|---|---|---|
| Alivernini et al.36 | MDA | MTX | Synovial CD3+ cells | Patients who reached MDA status at 6 months had lower baseline CD3+ cell immunohistochemistry scores |
| David et al.31 | DAS28 | bDMARD | HLA-B*27 allele | HLA-B*27 status was not associated with treatment response |
| Hellman et al.47 | MDA, DAPSA, ACR20/50/70 | ADA | HA in skin and serum | Higher levels of HA in serum associated with higher overall disease activity after 12 weeks of treatment |
| Mascia et al.32 | PsARC, ACR20 | TNFi | Genetic polymorphisms | SNP-29 predicts response to TNFi |
| Ørnbjerg et al.40 | DAPSA28 remission | TNFi | CRP | Normal CRP at baseline decreased the probability of DAPSA28 remission at 6 months |
| Siebert et al.46 | ACR20, PASI75 | GUS, UST | IL-17A, IL-17F, CRP | Baseline levels of proteins measured not associated with treatment response to UST. Baseline IL-17F modestly associated with ACR20 response to GUS |
| Song et al.45 | ACR20, PASI75 | GUS | CRP, SAA, slCAM1, svCAM1, IL-17A, IL-17F, IL-22 | None of the baseline proteins measured were associated with treatment response |
| Ovejero-Benito et al.33 | Improvement in Arthritis, EuroQol | ADA, ETN, IFX | Genetic polymorphisms | Association between polymorphisms in the TNFAIP3 gene and treatment response |
| Scrivo et al.41 | Achievement of MDA | GOL | hs-CRP | A higher baseline hs-CRP value and the absence of comorbidities were predictive factors for achieving MDA at 6 months |
| Muramatsu et al.48 | DAS28-CRP | IFX, ADA, UST | Serum IL-6 levels | Baseline serum IL-6 levels not statistically different between good responders and poor responders to treatment |
| Ademowo et al.37 | DAS28-CRP | ADA | Synovial tissue proteins | Panel of 57 proteins predictive of response to treatment (AUC of 0.76) |
| Collins et al.38 | DAS28 | TNFi | Synovial tissue proteins | 25 proteins differentially expressed between good and poor responders |
| Fabris et al.34 | Survival of first TNFi agent | TNFi | Genetic polymorphisms | TNFα -308A allele and IL-6 -174GG homozygosis resulted as independent biomarkers predicting survival of the first TNFi therapy |
| Murdaca et al.35 | ACR 20/50/70; DAS28; HAQ | ADA, ETN, IFX | Genetic polymorphisms | TNFα gene polymorphisms at −308 and −238 not associated with response to TNFi treatment. SNP +489 A/A genotype associated with response to ADA |
| Chandran et al.49 | SJC, TJC, PASI | ADA, ETN, IFX, GOL | MMP-3 | Baseline level of MMP-3 was independently associated with treatment response |
| Wagner et al.50 | ACR20; DAS28-CRP; PASI75 | GOL | 92 serum biomarkers | Pyridinoline, adiponectin, PAP and factor VII were identified as a panel of markers having the potential to be predictive of ACR20 response |
| Chimenti et al.51 | DAS28 | ETN, ADA | Complement C3 | Higher baseline C3 levels were associated with non-response |
| Marotta et al.52 | SJC68; PASI, CRP, ESR, DAS28, ACR50 | ADA | 14-3-3 eta serum protein | Baseline 14-3-3 eta titres were predictive of an ACR50 response |
| Pontifex et al.39 | DAS28 | ANR, ETN | CD3+ T cells (synovium & peripheral blood) | Baseline levels of CD3+ T cells were not predictive of treatment response |
| Pedersen et al.42 | VAS-pain; PGA; 28 joint count | ADA, ETN, IFX | CRP, IL-6, VEGF, YKL-40, MMP-3, total aggrecan | Baseline levels of serum CRP and MMP3 and plasma IL-6 and VEGF were all higher in responders compared to non-responders |
| Gratacos et al.43 | ACR50 | IFX | ESR, CRP | High CRP values were independently associated with a good therapeutic response |
| Kristensen et al.44 | TNFi survival | ADA, ETN, IFX | ESR, CRP | Higher baseline CRP levels associated with drug survival |
ACR, American college of rheumatology; ADA, adalimumab; ANR, anakinra; AUC, area under the curve; bDMARD, biologic DMARD; CAM, cell adhesion molecule; CRP, C-reactive protein; DAPSA, disease activity in psoriatic arthritis; DAS, disease activity score; ESR, erythrocyte sedimentation rate; ETN, etanercept; GOL, golimumab; GUS, guselkumab; HA, hyaluronan; HAQ, health assessment questionnaire; HLA, human leucocyte antigen; hs-CRP, high sensitivity CRP; IFX, infliximab; IL, interleukin; MDA, minimal disease activity; MMP, matrix metalloprotease; MTX, methotrexate; PASI, psoriasis area and severity index; PGA, patient global assessment; PsA, psoriatic arthritis; PsARC, psoriatic arthritis response criteria; SAA, serum amyloid A; SJC, swollen joint count; SNP, single nucleotide polymorphism; TJC, tender joint count; TNFi, TNF inhibitor; UST, ustekinumab; VAS, visual analogue score; VEGF, vascular endothelial growth factor.